Prot #CA209-76K: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma.

Project: Research project

Project Details

StatusActive
Effective start/end date7/1/207/1/23

Funding

  • Bristol-Myers Squibb Company (Prot #CA209-76K)